Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has moved a step closer to completing its $1.9 billion acquisition of Vicuron Pharmaceuticals after shareholders of the US biopharmaceutical company approved the deal.
Subscribe to our email newsletter
Conclusion of the transaction is now expected to occur in the third quarter of this year, subject to satisfaction of customary closing conditions, including regulatory approvals.
Vicuron has two new drug applications submitted to the FDA for its two lead products, dalbavancin, a novel intravenous antibiotic for the treatment of serious Gram-positive infections, and anidulafungin, a novel antifungal agent.
Vicuron applies a disciplined, integrated approach to anti-infective discovery for next-generation compounds in both hospital-based and community-acquired infections.